


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No. AM100389)



In re Application of: ) Appln. No.: 10/029,840  
 ) Confirmation No.: 5348  
 XIANG-JIN MENG et al. ) Group Art Unit: Unknown  
 ) Examiner: Unassigned  
 Filed: December 31, 2001 ) Paper No.: 10

For: AVIAN HEPATITIS E VIRUS, VACCINES AND METHODS OF  
PROTECTING AGAINST AVIAN HEPATITIS-SPLENOMEGALY  
SYNDROME AND MAMMALIAN HEPATITIS E

Commissioner for Patents  
Washington, D.C. 20231

#8  
MCW  
RECEIVED

MAY 08 2002

TECH CENTER 1600/296

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56 and pursuant to 37 C.F.R. § 1.97, Applicants wish to bring to the attention of the U.S. Patent and Trademark Office certain Chinese publications identified on the enclosed Form PTO-1449 (incorporated herein by reference thereto) that had not been received by the undersigned attorney in time to accompany the Information Disclosure Statement of April 1, 2002. A duplicate copy of Form PTO-1449 and a copy of each listed document are supplied herewith for the convenience of the Examiner. Two of the four Chinese documents provide an abstract in English as a part of the published document. English abstracts have been obtained and attached to the other two documents to briefly explain their relevancy as background to the present invention.

Applicants respectfully ask that the Examiner consider the listed items, initial the form, return a copy thereof to Applicants with the next communication and enter the original form into the application file.

Pursuant to 37 C.F.R. § 1.97(g) and (h), it is noted for the record that the filing of this supplemental information disclosure statement is not to be construed as a representation that a search has been made or as an admission that the listed items are, or are considered to be, material to patentability as defined in 37 C.F.R.

- 1 -

§ 1.56 or material to the examination of this application. Furthermore, this filing is not to be construed as a representation that additional information material to the patentability or the examination of this application does not exist; the information, protocols, results and the like reported by third parties are accurate or enabling; or the information constitutes prior art to the subject invention.

Favorable treatment of this application is urged.

Respectfully submitted,  
FORT DODGE ANIMAL HEALTH, INC.


Date: April 5, 2002

By: Anne M. Rosenblum  
Anne M. Rosenblum  
Attorney for Applicants  
Registration No. 30,419

FILING BY EXPRESS MAIL UNDER 37 C.F.R. § 1.10

This correspondence is being deposited with the U.S. Postal Service on April 5, 2002 to be delivered by the "Express Mail Post Office to Addressee" service under Mailing Label Number EK461082962US addressed to: Commissioner for Patents, Washington, D.C. 20231.

Anne M. Rosenblum  
Anne M. Rosenblum



**163 DELAWARE AVENUE • SUITE 212 • DELMAR, NEW YORK 12054 • TELEPHONE: (518) 475-0611**